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Atrial septal defect in infancy:
To close or not to close?
To the Editor:
I read with great interest the article by
Lammers and associates1 advocating that
closure of an atrial septal defect (ASD)
should not be postponed to a later age if
clinical problems that can be attributed at
least in part to the ASD are present. How-
ever, a closer look at the historical cohort
of Lammers and associates reveals that it is
composed mainly of premature syndromic
infants in whom the major issue is bron-
chopulmonary dysplasia and pulmonary
hypertension rather than left-to-right shunt
across the ASD.2 Hence the suggestion of
the authors, in the opinion of this reader, is
controversial.
Although ASD is the second most com-
mon congenital heart disease in children,3
there are still few unanswered questions
related to the appropriate timing of closure.
Because patients with even large ASDs are
mostly asymptomatic, closure is recom-
mended around 3 to 5 years of age, before
the child goes to school. Postponing surgi-
cal intervention to this age also allows for
spontaneous closure of the ASD in some
children.4 In fact, there does not appear to
be any significant benefit in ASD closure
before 3 to 5 years of age in small- to
moderate-sized defects.5
In the opinion of this reader, in the
present era of better ventilator equipment
and styles of ventilator management, along
with widespread use of corticosteroids pre-
natally and surfactant, nitric oxide, and pul-
monary vasodilator therapy postnatally,
surgical ASD closure can be postponed in
patients with compromised lung function
unless all available means of improving
lung function have been tried. Only when
pulmonary compromising factors have
been corrected will an attempt at surgical
ASD closure in infancy be valid because
even though mortality for major operations
with cardiopulmonary bypass in infants
with low weight has become low, a definite
morbidity still persists.
Shahzad G. Raja, MRCS
Department of Cardiac Surgery
Royal Hospital for Sick Children
Yorkhill NHS Trust
Dalnair St
Glasgow G3 8SJ
United Kingdom
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Reply to the Editor:
We appreciate Dr Raja’s interest in our
recent study.1
We agree that in asymptomatic children
closure of an isolated secundum-type atrial
septal defect (ASD II) should be under-
taken after 4 to 5 years of age because this
might allow for spontaneous closure and
facilitate interventional closure in some pa-
tients. However, we describe a specific
group of patients in whom symptoms have
been at least in part related to the presence
of an ASD II. In these patients with com-
promised lungs and rarefied pulmonary
vasculature, even a minor left-to-right
shunt is poorly tolerated, and early surgical
closure could be beneficial.
Our catheter data showed that the ma-
jority of the children had a left-to-right
shunt that varied in magnitude, as is dem-
onstrated by the Qp/Qs ratio. The actual
effect of the left-to-right shunt on the in-
fant’s clinical condition is difficult to as-
sess. However, the ASD is an additional
factor compromising the child’s situation.
One cannot treat lung hypoplasia or severe
chronic lung disease, but an ASD is ame-
nable to treatment.
There might be a subgroup of patients
in whom closure of an ASD is contraindi-
cated. In the presence of progressive pul-
monary vascular disease, the existence of
an ASD can improve survival.2
Dr Raja suggests that surgical ASD clo-
sure in infancy should only be performed
after all other compromising factors are
corrected. Yet even in the current era of
better ventilator management and use of
antenatal corticosteroids, nitric oxide, and
surfactant leading to improved survival of
infants, correction of the lung-compromising
factors is not always possible. Moreover,
long-term hospitalization and prolonged
ventilation of these children is associated
with substantial morbidity, including baro-
trauma, hospital-acquired infections, and
immobilization. Therefore we contend that
a subgroup of infants can indeed benefit
from early ASD closure. Careful patient
selection, however, remains a clinical chal-
lenge and requires a multidisciplinary ap-
proach involving cardiologists, intensivists,
and cardiothoracic surgeons to determine
the right timing of ASD closure for each
individual child.
Astrid Lammers
John Hess, MD, FESC
Klinik für Kinderkardiologie und angeborene
Herzfehler
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The evaluation of aortic
atherosclerosis and distensibility in
aortic valve stenosis—The role of
transesophageal echocardiography
To the Editor:
We read with great interest and congratulate
Weisenberg and associates on their trans-
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esophageal echocardiographic (TEE) study
entitled “Atherosclerosis of the aorta is
common in patients with severe aortic
stenosis: An intraoperative transesopha-
geal echocardiographic study.”1 This in-
triguing study found a strong association
between the presence of severe aortic ste-
nosis (AS) and the presence and severity
of aortic atheromas, suggesting that AS
might be a manifestation of the athero-
sclerotic process. However, we feel that a
few additional comments are necessary.
Evident from previous TEE work, we
demonstrated that the average grade of
aortic atherosclerosis (AA) using a five-
grade scale is significantly increased in
AS patients with normal epicardial coro-
nary arteries (1.440.64) as compared to
control subjects without valvular or cor-
onary heart disease (0.620.74). The de-
gree of AA in AS patients is also similar
to patients with significant left anterior
descending coronary artery (LAD) dis-
ease (1.27 0.72).2 Furthermore, another
TEE study verified that, neither age, gen-
der, high blood pressure, diabetes melli-
tus, hypercholesterolaemia nor coronary
flow velocity reserve were suitable for
the prediction of AS patients with signif-
icant LAD stenosis from AS subjects
with normal epicardial coronary arteries.
Only the grade of AA is suitable for the
prediction of AS patients with significant
LAD stenosis from AS subjects with nor-
mal epicardial coronary arteries. With re-
spect to demographic, clinical and echo-
cardiographic data, only the prevalence
of grade 2 or 3 AA (aortic plaque) is
significantly increased in AS patients
with significant stenosis of the LAD.3
Aortic distensibility can also be eval-
uated during TEE using aortic and blood
pressure data. Different elastic properties
of the descending aorta can be assessed
by TEE as elastic modulus and Young’s
circumferential static elastic modulus.
Decreased aortic distensibility (increased
elastic moduli) and thus, increased stiff-
ness of the descending aorta were dem-
onstrated in AS patients with normal epi-
cardial coronary arteries. This result
supports that decreased aortic distensibil-
ity in AS patients is an early manifesta-
tion of the atherosclerotic process and/or
decreased perfusion of the aorta.2,5 Our
initial results suggest that there are no
differences in these values characterizing
aortic distensibility if mitral stenosis is
associated with AS.4
Overall, these results confirm that
TEE is a valuable method for the mor-
phological (grade of aortic atherosclero-
sis) and functional (elastic properties of
the aorta) evaluation of the descending
aorta in AS patients. There is a strong
relationship between the aortic athero-
sclerosis/distensibility and AS, suggest-
ing that aortic valve calcification might
represent an atherosclerosis-like process.
However further investigations are war-
ranted.
Attila Nemes, MD, PhD, FESC
Tamás Forster, MD, PhD, DSc, FESC
Miklós Csanády, MD, PhD, DSc, FESC, FACC
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Association between
cyclooxygenase and epidermal
growth factor receptor pathways in
non–small cell lung cancer
To the Editor:
We read with great interest the article by
Sievers and associates.1 In their orthotopic
murine model of lung cancer with adenocar-
cinoma, they showed inhibition of tumor
growth with a low-dose cyclooxygenase-2
(COX-2) inhibitor, celecoxib. In their arti-
cle, they discussed different mechanisms of
association between COX-2 inhibition and
attenuation of tumor growth in non–small
cell lung cancer (NSCLC), and we want to
propose another. COX (or prostaglandin
endoperoxide synthase) catalyzes the con-
version of arachidonic acid to prostaglan-
din (PG) H2. This unstable endoperoxide is
then converted into PGE2, PGI2, PGD2,
PGF2, or thromboxane A2 by each respec-
tive PG synthase. Most tumors that express
COX have been found to contain high lev-
els of PGE2 and the microsomal PGE syn-
thase enzyme. Presumably, these bioactive
lipid products of COX, such as PGE2, are
responsible for some of the proneoplastic
effects mediated by this enzyme.2 The epi-
dermal growth factor receptor (EGFR) is a
member of the ErbB family of transmem-
brane tyrosine kinase receptors. The ex-
pression of EGFR is common in a number
of normal epithelial tissues, and the expres-
sion of EGFR is elevated in several solid
tumors. In NSCLC, overexpression of
EGFR has been reported to be present in
more than 50% of cases in several series.
Receptor activation leads to recruitment and
phosphorylation of several downstream intra-
cellular substrates, leading to mitogenic sig-
naling and other tumor-promoting cellular
activities. In addition to this, several retro-
spective studies have identified the expres-
sion of EGFR as a negative prognostic fac-
tor in patients with resected early NSCLC.3
Sheng and colleagues4 found that PGE2 ini-
tially binds t o its cognate receptor, EP4, in
LS-174T cells, which in turn activates sig-
nals that led to dramatic changes in cell
biology. One study demonstrated that the
PGE2-induced migration and invasion oc-
cur by rapid transactivation and phosphor-
ylation of EGFR in developing carcinoma
cells.5 Within minutes after treatment,
PGE2 induces the activation of Akt. This
effect is completely abolished by EGFR-
specific tyrosine kinase inhibitors, provid-
ing evidence for the role of the EGFR in
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